Asosiy kontentga oʻtish
Maqola

Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial

Stephen BagleyDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. [email protected]Zev A. BinderCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USALamia LamraniParker Institute for Cancer ImmunotherapyEliana MarinariDepartment of Oncology, University Hospital of Geneva, Geneva, SwitzerlandArati DesaiDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAMacLean P. NasrallahDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAEileen MaloneyDepartment of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USASteven BremDepartment of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USARobert A. LustigDepartment of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAGoldie KurtzDepartment of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAMichelle Alonso‐BasantaDepartment of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAPierre‐Emmanuel BontéInstitut CurieChristel GoudotUniversité Paris Sciences et LettresWilfrid RicherInstitut CurieEliane PiaggioUniversité Paris Sciences et LettresShawn KothariDepartment of Hematology and Medical Oncology, Emory University, Atlanta, GA, USALéa GuyonnetCytometry Platform, CurieCoreTech, Institut Curie, Paris, FranceCoralie L. GuérinCytometry Platform, CurieCoreTech, Institut Curie, Paris, FranceJoshua J. WaterfallDepartment of Translational Research, PSL Research University, Institut Curie Research Center, Paris, FranceSuyash MohanDepartment of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAWei‐Ting HwangDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAOliver Y. TangGBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAMeghan LogunCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAMeghna BhattacharyyaCooper Medical School of Rowan University, Camden, NJ, USAKelly MarkowitzDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USADevora DelmanDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAAmy MarshallCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAE. John WherryUniversity of PennsylvaniaSebastián AmigorenaInstitut CurieGregory L. BeattyDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USAJennifer L. BrogdonNovartis Institutes for BioMedical Research, Cambridge, MA, USAElizabeth O. HexnerDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USADenis MiglioriniAgora Cancer Research Center, Lausanne, SwitzerlandCécile AlanioInstitut CurieDonald M. O’RourkeCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
2024en
ABI

Annotatsiya

Annotatsiya mavjud emas.

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba